Last reviewed · How we verify
Sevoflurane inhalant product
Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.
Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling. Used for Induction and maintenance of general anesthesia in adults and pediatric patients, Sedation in mechanically ventilated patients in intensive care settings.
At a glance
| Generic name | Sevoflurane inhalant product |
|---|---|
| Also known as | Ultane, 74412392, Sevorane, Sevoflurane |
| Sponsor | Sunnybrook Health Sciences Centre |
| Drug class | Volatile inhalational anesthetic |
| Target | GABA-A receptor, NMDA glutamate receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Sevoflurane is a halogenated ether that acts as a general anesthetic by modulating multiple ion channels and neurotransmitter receptors in the brain. It enhances the activity of inhibitory GABA-A receptors while simultaneously blocking excitatory NMDA glutamate receptors, resulting in rapid loss of consciousness and anesthesia. The exact molecular mechanism remains incompletely understood but involves disruption of neuronal signaling at multiple levels.
Approved indications
- Induction and maintenance of general anesthesia in adults and pediatric patients
- Sedation in mechanically ventilated patients in intensive care settings
Common side effects
- Postoperative nausea and vomiting
- Emergence delirium
- Airway irritation
- Hypotension
- Bradycardia
- Hepatotoxicity (rare)
Key clinical trials
- SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (PHASE3)
- Sevoflurane and Dexmedetomidine's Contrasting Renal Impacts After Non-Cardiac Surgery (NA)
- Propofol or Sevoflurane Anesthesia in Egyptian Patients (NA)
- The Quality of Recovery From General Anesthesia With Desflurane for Fundus Surgery (EARLY_PHASE1)
- The Influence of Type of Anesthesia on Postoperative Pain (NA)
- Inhalational Anesthesia vs TIVA in Endoscopic Tympanoplasty (EARLY_PHASE1)
- Quantitative Electroencephalogram and Bispectral Index Brain Mapping During Propofol vs Sevoflurane General Anesthesia
- Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevoflurane inhalant product CI brief — competitive landscape report
- Sevoflurane inhalant product updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI